Clinical momentum LeonaBio is advancing a Phase 3 LASOFOXIFENE program for ESR1-mutated metastatic breast cancer with expected enrollment completion in 4Q 2026 and topline data in 2H 2027, signaling a near-term opportunity to align with oncology stakeholders and potential partnerships or licensing discussions.

ALS and breast focus The company targets high unmet needs in treatment-resistant ALS and ER-positive HER2-negative ESR1-mutated metastatic breast cancer, suggesting cross- therapuetic collaboration opportunities with hematology-oncology and neurology platforms, as well as patient advocacy channels.

Strategic partnerships Recent board enhancements and active participation in major conferences indicate a readiness to engage with investors and potential collaborators; leverage these moves to explore co-development, strategic investments, or out-licensing of lead candidates such as lasofoxifene and ATH-1105.

Financial runway With substantial funding and quarterly updates highlighting enrollment milestones and top-line timelines, there is a window for partner-led financing, royalty arrangements, or milestone-based deals tied to key clinical readouts and regulatory milestones.

Outreach channels The company’s tech stack and external-facing activity, including conference appearances and investor news, provide multiple touchpoints for outreach via KOLs, patient groups, and biotech brokers; tailor outreach to decision-makers in pharma licensing, BD, and clinical development.